Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the finalized design of its ...

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has finalized the design of its EXPRESS Phase 2 global clinical trial evaluating exaluren in patients with nonsense-mutation autosomal dominant polycystic ...

The Phase 1 study enrolled 25 healthy participants across three cohorts. The initial cohort received a single 500 mg dose under fed and fasted conditions, while subsequent cohorts received 750 mg once ...

Estuary Biotherapeutics has launched with $103 million in committed financing to develop genetic medicines targeting serious ...

Eloxx Pharmaceuticals said it has finalised the design of its planned global clinical trial in autosomal dominant polycystic kidney disease (ADPKD) following discussions with regulatory authorities ...

Seoul, Korea, Aug. 2, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in ...

SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated ...

Autosomal dominant polycystic kidney disease (ADPKD) causes cysts to grow in your kidneys. It's one of the most common genetic kidney diseases. ADPKD is inherited. It's caused by a change, or mutation ...

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary ...